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Acitretin mitigates 
uroporphyrin‑induced bone defects 
in congenital erythropoietic 
porphyria models
Juliana Bragazzi Cunha1,6*, Jared S. Elenbaas2,6, Dhiman Maitra1,6, Ning Kuo1, 
Rodrigo Azuero‑Dajud1, Allison C. Ferguson3, Megan S. Griffin3, Stephen I. Lentz4, 
Jordan A. Shavit3 & M. Bishr Omary1,5*
Congenital erythropoietic porphyria (CEP) is a rare genetic disorder leading to accumulation of uro/
coproporphyrin‑I in tissues due to inhibition of uroporphyrinogen‑III synthase. Clinical manifestations 
of CEP include bone fragility, severe photosensitivity and photomutilation. Currently there is no 
specific treatment for CEP, except bone marrow transplantation, and there is an unmet need for 
treating this orphan disease. Fluorescent porphyrins cause protein aggregation, which led us to 
hypothesize that uroporphyrin‑I accumulation leads to protein aggregation and CEP‑related bone 
phenotype. We developed a zebrafish model that phenocopies features of CEP. As in human patients, 
uroporphyrin‑I accumulated in the bones of zebrafish, leading to impaired bone development. 
Furthermore, in an osteoblast‑like cell line, uroporphyrin‑I decreased mineralization, aggregated 
bone matrix proteins, activated endoplasmic reticulum stress and disrupted autophagy. Using high‑
throughput drug screening, we identified acitretin, a second‑generation retinoid, and showed that it 
reduced uroporphyrin‑I accumulation and its deleterious effects on bones. Our findings provide a new 
CEP experimental model and a potential repurposed therapeutic.
Porphyrias are a group of inherited disorders due to defects in the heme biosynthetic  pathway1,2. One such 
example is congenital erythropoietic porphyria (CEP), most commonly caused by loss of function mutation in 
uroporphyrinogen III synthase (UROS; Fig.S1), the enzyme that catalyzes the third step of the heme biosyn-
thetic  pathway1,3. CEP is rare, with ~ 250 cases reported to  date4,5. It is autosomal recessive, and associated with 
reduced UROS activity (5% of normal) and consequent accumulation of uro/coproporphyrin-I (uro/copro-I) 
in bone marrow, erythrocytes, plasma, and increased uro/copro-I excretion in urine and  stool1,3,5,6. CEP is char-
acterized by severe photosensitivity, with skin fragility and blistering of sun-exposed  areas1,5,6. Scaring due to 
secondary skin infections and bone resorption contribute to disfigurement of light-exposed  areas3. Other clinical 
manifestations of this multisystem disease include chronic ulcerative keratitis, hemolysis, which may require 
repeated blood transfusions in severe cases, nonimmune hydrops fetalis, red urine since birth, erythrodontia 
and  osteodystrophy1,3,6,7. Currently, there is no specific pharmacological treatment for CEP, with interventions 
being life-style-related (e.g. avoidance of sun) or complex procedures, including bone marrow  transplantation3,8,9.
Fluorescent porphyrin accumulation in porphyria causes organelle specific protein oxidation and aggrega-
tion through mechanisms that involve type-II photosensitive reactions and secondary oxidative  stress10–17. We 
posit that porphyrin-mediated protein aggregation in CEP plays a major mechanistic role in tissue damage that 
involves accumulation of fluorescent uro/copro-I.
We demonstrated that uro-I injection of zebrafish larvae mimics features of CEP, including uro-I accumula-
tion in bones and bone deformation, as judged by decreased vertebra and operculum volume. Uro-I treatment 
of an osteoblastic human osteosarcoma cell line, Saos-2, caused significant decrease in mineral matrix synthesis 
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and proteotoxicity. Using high-throughput drug screening, we identified acitretin, a  2nd generation retinoid, as 
an effective drug that mitigates some of the harmful effects of uro-I in zebrafish and Saos-2 cells.
Results
An inducible zebrafish model mimics bone defects of human CEP. Uro-I injected zebrafish larvae 
showed porphyrin fluorescence in bone tissue (Fig. 1A). To confirm that uro-I binds specifically to bone, lar-
vae were co-injected with calcein (bone-specific dye) and imaged. Calcein and uro-I fluorescence co-localized 
(Fig. 1B), confirming uro-I bound to bone. Additionally, uro-I-injected larvae exhibited severe photosensitiv-
ity and had to be shielded from light to prevent their death (not shown). Next, we assessed uro-I-mediated 
bone defect by measuring the volume of the operculum and  4th vertebra. Notably, uro-I injection significantly 
decreased operculum and  4th vertebra volume (Fig. 1C).
Bone matrix is composed of protein/organic (including collagen/fibronectin/osteonectin) and inorganic com-
ponents (minerals, mostly hydroxyapatite)18,19. We tested whether uro-I binds to the protein/organic or inorganic 
parts of bone matrix by demineralizing bones of uro-I-injected larvae. Demineralization caused loss of uro-I 
fluorescence, indicating that uro-I is extractable from the mineral matrix (Fig. 1D). We validated this finding 
Figure 1.  Zebrafish model of CEP develops bone phenotype resembling human disease. (A) 6dpf zebrafish 
larvae were injected with uro-I or vehicle and imaged by confocal microscopy at 7dpf. Porphyrin was detected 
only in the bones of uro-I-injected group. Arrowhead-operculum; box-vertebrae. (B) Larvae were treated as in 
(A) and injected with calcein prior to imaging. Arrowhead-operculum; arrow-4th vertebra. (C) Quantification 
of bone volume in larvae from (B); bone volume was normalized to vehicle-injected larvae set to 100%. Symbols 
represent individual larvae (14–18/group) from 4–5 independent experiments. (D) Larvae were treated as 
in (A). At 7dpf bones were harvested and imaged by epifluorescence microscopy pre and post HCl bone 
demineralization, arrow-notochord. (E) Hydroxyapatite was incubated with calcein/uro-I/copro-I and imaged 
by epifluorescence microscopy. Scale bars: 200 µm (A-D); 50 µm (E). Three-dimensional image reconstruction 
(A, B) was performed using Imaris 3D software v7.7 (http:// imaris. oxinst. com/). **p < 0.01.
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in vitro using hydroxyapatite crystals. Uro-I, but not copro-I, bound to hydroxyapatite, with calcein binding 
used as a positive control (Fig. 1E). Therefore, uro-I binds to the inorganic bone matrix and its administration to 
zebrafish phenocopies three major features of CEP: osteal accumulation, bone defects, and severe photosensitivity.
Acitretin mitigates uro‑I effects in bones of zebrafish larvae. To identify potential drugs to treat 
CEP, we used our zebrafish CEP model and performed high-throughput screening of 1,280 small molecules by 
co-administering drug and uro-I injection (Fig.S2). Acitretin, a second-generation retinoid commonly used 
to treat psoriasis, decreased uro-I accumulation in bones (not shown). We validated the screening results and 
further characterized acitretin as a potential treatment for CEP by testing whether it had a prophylactic effect. 
Uro-I injected larvae were immediately transferred to either acitretin- or vehicle-containing medium. After 24 h, 
acitretin-treated larvae had significantly reduced porphyrin fluorescence in their bones (operculum and verte-
brae, Fig. 2A, B) and increased uro-I excretion into the medium (Fig. 2C), but no effect on operculum volume 
(Fig. 2D). To assess the therapeutic potential of acitretin, larvae were injected with uro-I then transferred after 
24 h to medium containing either acitretin or vehicle and incubated for further 24 h then imaged. Acitretin 
did not decrease bone porphyrin fluorescence (Fig. 2E, F), but it increased uro-I excretion to the medium and 
operculum volume (Fig. 2G, H).
Since acitretin is a retinoid, we tested whether the protective effects are specific to acitretin or shared by 
other retinoids. Etretinate (second-generation retinoid and precursor of acitretin), tretinoin (all trans-retinoic 
acid) or acitretin were co-administered to zebrafish with uro-I. In addition to acitretin, tretinoin significantly 
reduced bone porphyrin (Fig. 2I). Unlike acitretin, etretinate and tretinoin did not increase uro-I excretion into 
the medium (Fig. 2J), and retinoids did not prevent loss in bone volume (Fig. 2K). Thus, both retinoids, acitretin 
and tretinoin, prevent uro-I accumulation in zebrafish larvae. Hence, using our novel zebrafish CEP model, we 
demonstrated that acitretin attenuated uro-I-mediated bone damage by modulating the dynamics of uro-I bone 
binding and excretion.
Uro‑I impairs osteoblastic mineralization by aggregating matrix proteins, promoting ER 
stress and inhibiting autophagy. To elucidate the molecular mechanism of uro-I-mediated bone dam-
age, we used Saos-2 cells, a human osteosarcoma cell line with osteoblastic  features20. Mineralization was stimu-
lated by treating cells with a mineralization activation cocktail (MAC) and assayed by alizarin red S (ARS) 
staining. As expected, Saos-2 cells manifested a mineralization phenotype when cultured for 3 days in MAC-
supplemented medium, while in uro-I + MAC supplemented medium, mineralization decreased significantly 
(Fig. 3A, B). Uro-I also caused marked photosensitivity, leading to cell death when cells were not shielded from 
light (not shown).
Since fluorescent porphyrins cause protein aggregation or loss of antibody reactivity when tested by immuno-
blotting, we tested whether uro-I-mediated inhibition of Saos-2 mineralization led to aggregation of bone matrix 
proteins. Blotting Saos-2 cell lysates prepared from uro-I or vehicle treated cells using antibodies to fibronectin, 
osteonectin and type 1 pro-collagen showed a distinct loss of monomer for these proteins after uro-I treatment 
(Fig. 3C). We attribute the loss of antibody reactivity to epitope masking after uro-I binding and subsequent 
oxidation and aggregation, as shown previously for PP-IX13. The loss of matrix protein monomers and aggrega-
tion was verified by mass spectrometry (Fig.S3).
Given the effect of uro-I on protein aggregation, we tested whether uro-I treatment initiates unfolded pro-
tein response (UPR) and endoplasmic reticulum (ER) stress. We observed upregulation of BiP, consistent with 
UPR and ER  stress21 (Fig. 3C). Other ER stress markers, including PERK, IRE1α and ATF6, were likely oxidized 
and aggregated, as judged by monomer loss (Fig. 3C). Our findings suggest a non-canonical form of ER stress, 
which we have observed upon PP-IX  accumulation13, that involves aggregation and possibly inactivation of ER 
resident proteins and chaperones.
Autophagy modulates exocytosis of hydroxyapatite crystals and thus plays an important role in bone miner-
alization by  osteoblasts22,23. Since uro-I inhibited mineralization, we tested whether it also disrupted autophagy. 
As expected, MAC-treated Saos-2 cells showed increased LC3-II (Fig. 3D, left panel). Uro-I treatment also 
increased LC3-II levels (Fig. 3D, right panel). The likely explanation for the increased LC3-II is not increased 
autophagy but a slowing of autophagic flux, which could lead to stalling of exocytosis of mineral-loaded vesicles 
and decreased mineralization of bone  matrix24.
To further characterize uro-I-mediated impairment of mineralization in Saos-2 cells, we performed gene 
expression analysis to probe for alterations in the stress response pathway. Genes that were differentially regu-
lated two-fold or more after uro-I treatment were assessed further. Uro-I treatment increased HSPA5 (2.1x) 
and SOD3 (2.8x), while SERPINH1 decreased (3.3x) (Fig. 3E, left panel). Since HSPA5 encodes BiP, HSPA5 
upregulation supports the BiP upregulation observed biochemically (Fig. 3C). SERPINH1, a collagen-specific 
chaperone, downregulation may account for collagen misfolding and aggregation. Because type 1 collagen is 
the most abundant protein in bone  matrix25, we assessed COL1A1 expression and observed a 90% reduction in 
COL1A1 after uro-I treatment (Fig. 3E, right panel). This finding supports uro-I-induced loss of mineralization, 
since collagen serves as a matrix for mineral deposition.
We next asked whether acitretin can protect from the effects of uro-I, by treating Saos-2 cells with uro-I in 
the presence of acitretin. Although acitretin did not prevent uro-I-mediated loss of mineralization (Fig. 3F), it 
blunted the ER stress response by reducing BiP level and normalized the autophagic flux by reducing LC3-II 
(Fig. 3G, H). Acitretin also downregulated SOD3 3.8-fold, thereby suggesting that acitretin mitigates the oxida-
tive stress caused by uro-I (Fig. 3I). Upregulation of COL1A1 (1.7x) and SERPINH1 (5.4x) was also observed.
Taken together, our data demonstrate that acitretin mitigates uro-I-mediated proteotoxicity and oxidative 
stress. However, under the conditions tested, acitretin did not rescue the impairment of mineralization caused 
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Figure 2.  Acitretin mitigates CEP bone phenotype in zebrafish. (A) 6dpf larvae were injected with uro-I and transferred to medium 
containing acitretin or DMSO. At 7dpf larvae were injected with calcein and imaged by confocal microscopy. Quantification of 
porphyrin fluorescence (B), porphyrin excretion (C) and operculum volume (D) from experiment in (A). Symbols represent 
individual larvae (12–25/group) from 3–4 independent experiments. (E) 6dpf larvae were injected with uro-I. At 7dpf they were 
transferred to medium containing acitretin or DMSO. At 8dpf larvae were injected with calcein and imaged by confocal microscopy. 
Quantification of porphyrin fluorescence (F), porphyrin excretion (G) and operculum volume (H) from experiment in (E). 
Arrowhead-operculum; box-vertebrae (A, E). Symbols represent individual larvae (18–64/group) from 3–4 independent experiments. 
(I-K) Larvae were treated as in (A) with the indicated retinoid or DMSO and porphyrin fluorescence (I), porphyrin excretion (J) 
and operculum volume (K) were assayed. Bone volume was normalized to DMSO-treated larvae set to 100%, (D, H, K). Porphyrin 
excretion was normalized to DMSO-treated larvae set to 100%, (C, G, J). Symbols represent individual larvae (7–44/group) from 
2–4 independent experiments. Scale bars: 200 µm. Three-dimensional image reconstruction (A, E) was performed using Imaris 3D 
software v7.7 (http:// imaris. oxinst. com/). *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.
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Figure 3.  Saos-2 cells mimic CEP zebrafish model. (A, B) Mineralization in Saos-2 cells treated with MAC ± Uro-I 
was assayed using ARS staining (photograph, A; quantification, B). Staining was normalized to MAC only-treated cells 
(set to 100%). (C) Cell lysates from experiment in (A) were blotted with the indicated antibodies. (D) Quantification 
of LC3-II shown in (C). LC3-II level was normalized to MAC only (left panel) or vehicle-treated (right panel), set 
to 100%. (E)  RT2 Profiler PCR Array (left panel) and qPCR (right panel). Relative gene expression is represented 
as fold change normalized to housekeeping gene. Data are from 2 independent experiments. (F) Acitretin does not 
rescue reduced mineral matrix phenotype in uro-I-treated cells. ARS staining quantification as in (B). (G) Acitretin 
normalizes ER stress (BiP) and autophagy (LC3-II) markers. Dashed lines represent non-adjacent lanes in the gel. 
Coomassie-stained gel (C,G) shows equal protein loading. Full-length blots and gels (C,G) are presented in Fig.S4. 
(H) Quantification of LC3-II. LC3-II level was normalized to DMSO-treated cells set to 100%. (I) Gene expression 
profiling as in (E). *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.
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by uro-I treatment of Saos-2 cells. A possible explanation for why mineralization was not normalized by acitretin 
is that ER stress and autophagy pathways need to be normalized in order for cells to have their mineralization 
ability restored. Alternatively, acitretin may act differently on various cell types which is one major advantage 
offered by the in vivo zebrafish system.
Discussion
Uro-I is a fluorescent porphyrin capable of types I/II-photosensitized  reactions26–28, which explains the observed 
photosensitivity in CEP, damage to digits and facial  features3. However, light is unlikely to reach deep internal 
tissues, which are also affected in CEP. Of note, we observed uro-I-mediated protein aggregation and decreased 
mineralization in the dark. Previous studies had also reported dark effects of porphyrins. For example, uro-I 
increased collagen biosynthesis in human skin  fibroblasts29, and inhibited erythrocytic uroporphyrinogen decar-
boxylase  activity30. A 2-hit model could explain light-independent porphyrin-mediated protein aggregation 
and proteotoxicity whereby, in absence of light, a secondary oxidant source (eg. inflammatory cells) causes 
protein oxidation followed by porphyrin binding to oxidized protein, yielding protein  aggregates11,12 (Fig. 4). 
CEP is frequently associated with superinfections and  osteolysis3,31. Hence, infiltrating immune cell-generated 
oxidants might serve as a secondary source of oxidant, leading to uro-I mediated protein aggregation in internal 
organs such as bones. Additionally, uro-I might generate oxidants by acting as a substrate for the ferredoxin/
ferredoxin:NADP + oxidoreductase  system32. Although ferredoxin/ferredoxin:NADP + oxidoreductase are com-
monly associated with hepatic microsomes, they are also expressed in  osteoblasts33 and could metabolize uro-I 
to generate oxidants in the absence of light.
The differences in charge and polarity of uro-I and PP-IX might explain the striking difference in their tissue 
localization. Retro-orbitally injected PP-IX accumulated in zebrafish  liver10, while uro-I accumulated preferen-
tially in bone (Fig. 1). Of note, liver cancer cell lines do not uptake uroporphyrin (unpublished data), possibly 
Figure 4.  Proposed model of CEP pathogenesis. UROS inhibition leads to production of uro/copro-I mostly in 
erythrocytes and liver, which is transported through blood to the bones. Uro-I causes bone damage by binding 
to hydroxyapatite, causing oxidative and ER stress, protein aggregation and stalled autophagy. Acitretin partially 
rescues uro-I-induced bone damage by reducing oxidative and ER stress and restoring autophagic flux.
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due to its high negative charge that prevents traversing the cell  membrane34. Based on our data, we propose that 
negatively charged uro-I binds to  Ca2+ in hydroxyapatite (Fig. 4) and thus bone and Saos-2 cells are affected by 
uro-I. This association with bone matrix causes uro-I to have a different protein aggregation signature compared 
to PP-IX, which is primarily internalized. PP-IX aggregated intracellular proteins such as keratins and glycer-
aldehyde 3-phosphate  dehydrogenase13,15,35, whereas uro-I affected extracellular bone matrix proteins (Fig. 3). 
Oxidants such as singlet oxygen, a major oxidant produced by photosensitive  reactions26, have extremely small 
intracellular diffusion distance (10-20 nm) and lifetime (10–40 ns)36–38. Binding of uro-I to bone matrix causes 
a ‘sensitizer-acceptor’ coupling, as observed for other diffusible  oxidants39,40, and greatly increases the oxidation 
efficiency and specificity. Of note, oxidized fibronectin reduces mineralization of rat calvarial osteoblasts in 
vitro41. The high selectivity of uro-I localization to bone matrix might provide a pathway to develop photody-
namic therapeutic agents for bone cancers such as osteosarcoma.
The management of CEP is challenging, with current therapeutic options focusing on bone marrow/hemat-
opoietic stem cell  transplantation3, and by avoidance of sun and light exposure, including the use of protective 
 clothing42–45. There are also potential experimental therapeutic approaches including gene  therapy46, proteasomal 
 inhibitors47,48, iron  chelation49,50 and  phlebotomy51. Most recently, the repurposed use of ciclopirox, an approved 
broad-spectrum antifungal agent, showed promising results in the treatment of CEP using a mouse  model52. 
However, there are limitations to these approaches, such as complications from transplantation and neurotoxic 
side effects of proteasome  inhibitors53. Currently there are no known pharmaceuticals that act by clearance of 
uro-I, and in this regard acitretin provides a novel approach. Acitretin might also act as an antioxidant (Fig. 4) 
due to its hyperconjugated nucleophilic double bonds. Thus, through a combination of destabilizing uro-I-bone 
matrix interaction and antioxidant activity, acitretin could ameliorate CEP manifestations (Fig. 4). Acitretin also 
offers a drug repurposing advantage since it is already approved for psoriasis  treatment54.
Materials and methods
Zebrafish experiments and cell culture. Zebrafish (Danio rerio) experiments were conducted using 
ABxTL hybrid and NHGRI-1 wild type zebrafish lines. All animal procedures were approved by the Rutgers 
University Institutional Animal Care and Use Committee (protocol number PROTO201900147) and performed 
in compliance with federal guidelines and the standards of the NIH Guide for the Care and Use of Laboratory 
 Animals55, the Rutgers University IACUC Policy Handbook and the Animal Research: Reporting of In Vivo 
Experiments (ARRIVE) guidelines.
Saos-2 cells were purchased from ATCC. Cells were maintained in McCoy 5A medium supplemented with 
15% FBS, penicillin/streptomycin, non-essential amino acids, Hepes and L-glutamine. To induce mineralization, 
cells were treated with mineralization activation cocktail (MAC), consisting of 5 mM β-glycerophosphate, 50 
µM ascorbic acid and 10 nM  dexamethasone56.
Uro‑I solution preparation and treatment of zebrafish larvae and Saos‑2 cells. Uro-I (uropor-
phyrin-I dihydrochloride; Frontier Scientific, Catalog#:U830-1) was initially resuspended in 0.1 M NaOH and 
the pH was adjusted to neutral using 0.2 M  Na2HPO4. Six days post fertilization (dpf), ABTL zebrafish larvae 
were injected via the retro-orbital route with approximately 3nL of 7.2 mM uro-I solution and control larvae were 
injected with vehicle (0.1 M NaOH in 0.2 M  Na2HPO4). After injection, larvae were immediately transferred to 
Petri dishes wrapped with heavy duty aluminum foil and kept in a dark incubator, at 28.5 °C for 24 h. Where 
indicated, 7 dpf larvae were injected with approximately 2 nL of 0.2% w/v calcein (Sigma, Catalog#:C0875) 2 h 
prior to imaging.
Saos-2 cells were plated in 12-well plates (1.5 ×  105 cells/well) and allowed to attach overnight. Cells were then 
treated with uro-I (144 µM final concentration) or vehicle in medium containing MAC for 3 days. Experiments 
were conducted in a dark room and cells were kept shielded from light in a tissue culture incubator.
Confocal microscopy imaging and quantification. Seven dpf ABxTL zebrafish larvae were anesthe-
tized with tricaine-S (Syndel) and immobilized in 0.5% low melt agarose. Fluorescent z-series were captured 
using an Olympus FV500 confocal microscope (10X objective, confocal aperture of 300 µµ) with an optical 
thickness of 10 µm and z-step size of 10 µm. Calcein was excited with a 488 nm argon laser and emission was 
captured between 505 and 525 nm. Porphyrin was excited with a 405 nm laser diode and emission was captured 
above 560 nm. Three-dimensional image reconstruction and quantification of fluorescent signal and bone vol-
ume were performed using Imaris 3D visualization and analysis software v7.7 (Bitplane).
In vivo and in vitro binding of uro‑I. Six dpf ABxTL zebrafish larvae were injected with uro-I or vehicle 
(as described above) and 24 h later were euthanized by tricaine-S overdose on ice bath. Bones were harvested as 
previously  described57. Briefly, soft tissue was removed by incubating larvae with Accumax solution (Millipore-
Sigma, Catalog#:A7089) under vigorous shaking. Bones were collected using a 70 µm cell strainer, followed by 
demineralization with 1.2 M HCl. Fluorescent images were captured prior to and after the demineralization step 
using a Zeiss Axio Imager M2 fluorescence microscope. Porphyrin signal was captured using the red fluorescent 
channel.
10 mg hydroxyapatite (Acros Organics, Catalog#:1306–06-5) was incubated with 1 mM uro-I, 1 mM copro-I 
(coproporphyrin-I dihydrochloride, Frontier Scientific, Catalog#:C654-1), vehicle or 0.2% calcein for 30 min 
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High throughput drug screening. Unbiased high throughput drug screening was performed using the 
Prestwick library (Prestwick Chemical), which consists of 1,280 small molecules chosen by the manufacturer 
for their bioavailability and safety. A pooled approach, where four compounds were tested together, was used in 
order to optimize animal use and investigation of drugs with potential for CEP treatment. Zebrafish E3 medium 
(100 µL/well) was transferred to a 96-well half area imaging plate (Corning, cat. n. 3880) using a Multidrop 
dispenser (ThermoFisher Scientific). Compounds (0.4 µL of 2 mM stock) were added to the wells using a multi-
channel plate handling robot (Biomek FX, Beckman Coulter Life Sciences). This step was performed four times 
in order to pool four compounds into one well: one 384-well stock plate yielded one 96-well test plate. Control 
wells contained 1.6 µL of DMSO.
Six dpf NHGRI-1 zebrafish larvae were injected retro-orbitally with approximately 2nL of a solution of uro-I 
(10 mM) and calcein (0.2% w/v). Immediately after injection, larvae were transferred to a 96-well test plate (two 
larvae in 50 µL of E3 medium/well), including the DMSO control wells. Larvae were kept in the dark, at 28.5 °C. 
After 24 h, they were anesthetized with tricaine-S, centrifuged at 500xg for two minutes and imaged using the 
ImageXpress Micro Cellular Imaging and Analysis System (Molecular Devices). Positive hits were selected based 
on visual identification of calcein signal increase and porphyrin signal decrease compared to DMSO-treated 
larvae. Compounds in test wells that met the inclusion criterion were tested individually in the same manner as 
described above (Figure S2).
Acitretin validation and treatment. A dose-response curve with acitretin (Selleck Chemicals, Houston, 
TX) was conducted (0.5–12.5 µM) and 10 µM was observed to yield consistent results, without being toxic to 
zebrafish larvae. Validation and characterization of acitretin as a potential treatment for CEP was performed. Six 
dpf ABxTL zebrafish larvae injected with uro-I were immediately transferred to 10 cm plastic dishes containing 
10 µM acitretin or DMSO in E3 medium (prophylaxis protocol, Fig. 2A), and incubated for 24 h in the dark at 
28.5 °C. Porphyrin binding to bones and bone volume were analyzed by confocal microscopy as described above. 
Porphyrin excretion into the medium was quantified. Uro-I-injected larvae were transferred to 96-well plates, 
one larva/well, 100µL of 10 µM acitretin or DMSO/well. Medium was collected after 24 h and porphyrin was 
quantified as described  previously13. Etretinate (Selleck Chemicals, Houston, TX) and tretinoin (Selleck Chemi-
cals, Houston, TX) treatment was performed as described for acitretin.
In addition to being used as prophylaxis, we evaluated whether acitretin had a therapeutic effect. Six dpf 
ABxTL zebrafish larvae were injected with uro-I and 24 h later they were transferred to E3 medium containing 
10 µM acitretin or DMSO. Porphyrin binding, excretion and bone volume were analyzed as described above. For 
Saos-2 cells, they were treated with 10 µM acitretin or DMSO in medium containing MAC and uro-I.
Alizarin Red S (ARS) staining and quantification. Cell mineralization was quantified by ARS (Sigma 
Aldrich St. Louis, MO) staining as described  previously58 with minor modifications. Briefly, cells were fixed with 
100% ethanol at 37 °C for 1 h, stained with 40 mM (pH4.2) ARS solution for 20 min in an orbital shaker. Cells 
were washed and ARS was extracted by incubation of fixed cells with 10% (v/v) acetic acid, followed by scrap-
ing, incubation of suspension (85 °C, 10 min), centrifugation and neutralization of supernatant with 10% (v/v) 
ammonium hydroxide. ARS standard curve (from 2–0.02 mM) and samples were transferred in triplicate to a 
96-well plate and absorbance was measured at 405 nm.
Cell harvest, immunoblotting and mass spectrometry. Saos-2 cells were lysed in ice cold RIPA 
buffer (Sigma Aldrich, St. Louis, MO) with protease inhibitor cocktail (Thermo Scientific, Waltham, MA) and 
scraped. Whole cell lysate was kept in the dark until reducing SDS-PAGE sample buffer was added. Immunob-
lotting, band densitometry and mass spectrometry were conducted as described  previously12,13. The antibodies 
used and their vendors are as listed. Antibodies to the indicated antigens (and sources) are: ATF6, BiP, LC3B 
(Cell Signaling Technology, Danvers, MA); fibronectin HFN 7.1, pro-collagen SP1.D8, osteonectin AON-1 
(Developmental Studies Hybridoma Bank; Iowa City, Iowa); IRE1α, PERK (Invitrogen, Carlsbad, CA); lamin 
A/C (Santa Cruz Biotechnology, Dallas, TX).
Gene expression profiling. Saos-2 cells RNA was extracted using RNeasy mini kit (Qiagen, Cata-
log#:74,104). and gene expression was carried using the  RT2 Profiler PCR Array for human cellular stress 
responses (Qiagen, Catalog#:PAHS-019ZA) following manufacturer’s instructions. A previously described 
 qPCR59 was performed for COL1A1 and SERPINH1 (IDT Integrated DNA Technologies, PrimeTime assay ID 
Hs.PT.58.15517795 and Hs.PT.56a.26865778, respectively).
Statistical analysis. Statistical analysis was performed using GraphPad Prism v8 (GraphPad Software). 
Unpaired two-tailed Student’s t-test was used to determine statistical significance. Error bars represent standard 
error of the mean. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.
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